Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure

• US 20060008450A1
• Filed: 06/13/2005
• Published: 01/12/2006
• Est. Priority Date: 08/05/1999
• Status: Active Grant

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Verfaillie, Catherine M., Furcht, Leo T., Reyes, Morayma
• Granted Patent: US 8,075,881 B2
• Time in Patent Office: Days
• US Class Current: 424/93.210
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/34 Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes vascular smooth muscle A61K35/44
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 2500/36 Lipids
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2501/105 Insulin-like growth factors [IGF]
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 2501/235 Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 2501/33 Insulin together with transferrin C12N2500/25; Insulin-like growth factors C12N2501/105
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2533/52 Fibronectin; Laminin
• CPC Class Codes: C12N 5/0607 Non-embryonic pluripotent stem cells, e.g. MASC induced pluripotent stem cells C12N5/0696

Abstract

The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells in cardiac indications.

Claims

1. A method of providing cardiac muscle to a subject in need thereof, comprising administering to the subject, in an amount effective to provide new cardiac muscle, an isolated population of non-ES, non-germ, and non-embryonic germ cells that are positive for telomerase and can differentiate into ectodermal, endodermal, and mesodermal cell types.

4. The method of claim 1, wherein the existing cardiac muscle is damaged by disease or injury.

5. The method of claim 4, wherein the disease is selected from the group consisting of congestive heart failure, coronary artery disease, myocardial infarction, myocardial ischemia, atherosclerosis, cardiomyopathy, idiopathic cardiomyopathy, cardiac arrhythmias, muscular dystrophy, muscle mass abnormality, muscle degeneration, infective myocarditis, drug- or toxin-induced muscle abnormalities, hypersensitivity myocarditis, autoimmune endocarditis, and congenital heart disease.

6. The method of claim 1, wherein the isolated cells are expanded in cell culture medium prior to administration to the subject.

9. The method of claim 1, wherein the isolated cells are administered using techniques selected from the group consisting of surgical intramyocardial injection, transendocardial injection, intracoronary injection, transvascular injection, intramuscular injection, intravenous injection and cardiac catheter administration.

2. A method of increasing cardiac muscle function comprising contacting an amount of an isolated population of non-ES, non-germ, and non-embryonic germ cells that are positive for telomerase and can differentiate into ectodermal, endodermal, and mesodermal cell types with existing cardiac muscle effective to increase cardiac muscle function.

7. The method of claim 2, wherein the isolated cells are expanded in cell culture medium prior to contacting existing cardiac muscle.

10. The method of claim 2, wherein the isolated cells contact existing cardiac muscle using techniques selected from the group consisting of surgical intramyocardial injection, transendocardial injection, intracoronary injection, transvascular injection, intramuscular injection, intravenous injection and cardiac catheter administration.

3. A process for producing cardiac muscle cells in a subject comprising administering to the subject, in proximity to existing cardiac muscle and in an amount effective to produce cardiac muscle cells, an isolated population of non-ES, non-germ, and non-embryonic germ cells that are positive for telomerase and can differentiate into ectodermal, endodermal, and mesodermal cell types.

8. The method of claim 3, wherein the isolated cells are expanded in cell culture medium prior to administration to the subject.

11. The method of claim 3, wherein the isolated cells are administered using techniques selected from the group consisting of surgical intramyocardial injection, transendocardial injection, intracoronary injection, transvascular injection, intramuscular injection, intravenous injection and cardiac catheter administration.